European Journal of Medicinal Chemistry, volume 274, pages 116532
Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy
Shanshan Ma
1
,
Guanlu Long
1
,
Zheng Jiang
1
,
Yan Zhang
1
,
Liangkui Sun
1
,
Yun Pan
2
,
Qidong You
1, 2
,
Xiaoke Guo
1, 2
Publication type: Journal Article
Publication date: 2024-08-01
scimago Q1
wos Q1
SJR: 1.151
CiteScore: 11.7
Impact factor: 6
ISSN: 02235234, 17683254
Abstract
Histone H3 lysine 36 (H3K36) methylation is a typical epigenetic histone modification that is involved in various biological processes such as DNA transcription, repair and recombination in vivo. Mutations, translocations, and aberrant gene expression associated with H3K36 methyltransferases have been implicated in different malignancies such as acute myeloid leukemia, lung cancer, multiple myeloma, and others. Herein, we provided a comprehensive overview of the latest advances in small molecule inhibitors targeting H3K36 methyltransferases. We analyzed the structures and biological functions of the H3K36 methyltransferases family members. Additionally, we discussed the potential directions for future development of inhibitors targeting H3K36 methyltransferases.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.